Prevalence, risk and severity of SARS-CoV-2 infections in psoriasis patients receiving conventional systemic, biologic or topical treatment during the COVID-19 pandemic: a cross-sectional cohort study (PsoCOVID)
The risk of SARS-CoV-2 infection does not appear to be increased for psoriasis patients using biologics compared to those on other treatments, but evidence is still limited. (1) to estimate the prevalence of SARS-CoV-2 infection in patients with psoriasis, (2) to compare SARS-CoV-2 infection rates f...
Gespeichert in:
| Veröffentlicht in: | The Journal of dermatological treatment 2023-12, Vol.34 (1), p.2161297-2161297 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 2161297 |
|---|---|
| container_issue | 1 |
| container_start_page | 2161297 |
| container_title | The Journal of dermatological treatment |
| container_volume | 34 |
| creator | Kwee, Kevin V. Murk, Jean-Luc Yin, Qiqi Visch, M. Birgitte Davidson, Linda de Jong, Elke M. G. J. van den Reek, Juul M. P. A. Tjioe, Milan |
| description | The risk of SARS-CoV-2 infection does not appear to be increased for psoriasis patients using biologics compared to those on other treatments, but evidence is still limited.
(1) to estimate the prevalence of SARS-CoV-2 infection in patients with psoriasis, (2) to compare SARS-CoV-2 infection rates for different psoriasis treatments groups (biologic vs. systemic conventional vs. topical therapy) corrected for confounders and (3) to describe patients with severe COVID-19 for all treatment groups.
In this cross-sectional cohort study all patients received a questionnaire to gather data on psoriasis treatment, SARS-CoV-2 infections and related risk factors. Simultaneously, they underwent a blood test to screen for antibodies to SARS-CoV-2 N-antigen. Prevalence of SARS-CoV-2 infections was calculated and logistic regression and Cox proportional-hazards models were performed to determine the association between treatment group and SARS-CoV-2 infection risk, corrected for confounders. Patients with severe COVID-19 disease were described and the mortality rate per treatment group was calculated for the target population.
Patients were included between April 12 2021 and October 31 2021. Of 551 patients, 59 (10.7% (CI95% 8.3-13.6)) had experienced a SARS-CoV-2 infection, based on questionnaire data combined with serological data. In our study cohort, corrected for confounders, biologic or non-biologic systemic therapy users did not appear to have increased SARS-CoV-2 infection risk compared to patients using other treatment. Only 4 hospitalizations (0.7% (CI95% 0.2-1.0) were reported in our study population and no ICU admissions were reported. The rough mortality rate in the target cohort was 0.32% (CI95% 0.13-0.66) in all treatment groups.
Corrected for risk-mitigating behavior and vaccination status, a higher SARS-CoV-2 incidence for biologics or non-biologics systemics compared to other treatments could not be proven. Severe cases were infrequent in all treatment groups. This finding further strengthens treatment recommendations that systemic therapies for patients with psoriasis do not require preventive cessation for reduction of SARS-CoV-2 infection risk. |
| doi_str_mv | 10.1080/09546634.2022.2161297 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmed_primary_36545844</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_5bbb433f11f24b4ebee8812a7667dde9</doaj_id><sourcerecordid>2757056820</sourcerecordid><originalsourceid>FETCH-LOGICAL-c479t-c55db7856379bb8a329a0b95c602fb9f52d4b098b2bb9cc8b41b8ef3950f17143</originalsourceid><addsrcrecordid>eNp9kt9u2yAYxa1p05p1e4RNXHZSnQEGY3bVKvsXqVKrdestAvw5pbNNBiRTnnMvNJykvdwV6ON3zkFwiuItwXOCG_wBS87qumJziimdU1ITKsWzYkaYICURvHpezCamnKCT4lWMDxiTqsbNy-KkqjnjDWOz4u9NgK3uYbRwjoKLv5AeWxRhC8GlHfIdur38flsu_F1JkRs7sMn5MeYtWkcfnI4uorVODsYUUQALbuvGFbJ-3OZRZnWP4i4mGJw9R8b53q-cRT6g5NfO5tMUQKchw6jdhEmb7gEtru-Wn0ois_fYTtqPSCMbfIxlPNwhK62_9yGhmDbtDp3dRL9XvX9dvOh0H-HNcT0tfn75_GPxrby6_rpcXF6VlgmZSst5a0TD60pIYxpdUamxkdzWmHZGdpy2zGDZGGqMtLYxjJgGukpy3BFBWHVaLA--rdcPah3coMNOee3UfuDDSumQnO1BcWMMq6qOkI4yw8AANA2hWtS1aFuQ2evs4LUO_vcGYlKDixb6Xo_gN1FRwQXmdUNxRvkB3T9HgO4pmmA1dUM9dkNN3VDHbmTdu2PExgzQPqkey5CBiwOQ_9mHQf_xoW9V0rvehy7o0bqoqv9n_AN5uMun</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2757056820</pqid></control><display><type>article</type><title>Prevalence, risk and severity of SARS-CoV-2 infections in psoriasis patients receiving conventional systemic, biologic or topical treatment during the COVID-19 pandemic: a cross-sectional cohort study (PsoCOVID)</title><source>Taylor & Francis Open Access</source><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><creator>Kwee, Kevin V. ; Murk, Jean-Luc ; Yin, Qiqi ; Visch, M. Birgitte ; Davidson, Linda ; de Jong, Elke M. G. J. ; van den Reek, Juul M. P. A. ; Tjioe, Milan</creator><creatorcontrib>Kwee, Kevin V. ; Murk, Jean-Luc ; Yin, Qiqi ; Visch, M. Birgitte ; Davidson, Linda ; de Jong, Elke M. G. J. ; van den Reek, Juul M. P. A. ; Tjioe, Milan</creatorcontrib><description>The risk of SARS-CoV-2 infection does not appear to be increased for psoriasis patients using biologics compared to those on other treatments, but evidence is still limited.
(1) to estimate the prevalence of SARS-CoV-2 infection in patients with psoriasis, (2) to compare SARS-CoV-2 infection rates for different psoriasis treatments groups (biologic vs. systemic conventional vs. topical therapy) corrected for confounders and (3) to describe patients with severe COVID-19 for all treatment groups.
In this cross-sectional cohort study all patients received a questionnaire to gather data on psoriasis treatment, SARS-CoV-2 infections and related risk factors. Simultaneously, they underwent a blood test to screen for antibodies to SARS-CoV-2 N-antigen. Prevalence of SARS-CoV-2 infections was calculated and logistic regression and Cox proportional-hazards models were performed to determine the association between treatment group and SARS-CoV-2 infection risk, corrected for confounders. Patients with severe COVID-19 disease were described and the mortality rate per treatment group was calculated for the target population.
Patients were included between April 12 2021 and October 31 2021. Of 551 patients, 59 (10.7% (CI95% 8.3-13.6)) had experienced a SARS-CoV-2 infection, based on questionnaire data combined with serological data. In our study cohort, corrected for confounders, biologic or non-biologic systemic therapy users did not appear to have increased SARS-CoV-2 infection risk compared to patients using other treatment. Only 4 hospitalizations (0.7% (CI95% 0.2-1.0) were reported in our study population and no ICU admissions were reported. The rough mortality rate in the target cohort was 0.32% (CI95% 0.13-0.66) in all treatment groups.
Corrected for risk-mitigating behavior and vaccination status, a higher SARS-CoV-2 incidence for biologics or non-biologics systemics compared to other treatments could not be proven. Severe cases were infrequent in all treatment groups. This finding further strengthens treatment recommendations that systemic therapies for patients with psoriasis do not require preventive cessation for reduction of SARS-CoV-2 infection risk.</description><identifier>ISSN: 0954-6634</identifier><identifier>EISSN: 1471-1753</identifier><identifier>DOI: 10.1080/09546634.2022.2161297</identifier><identifier>PMID: 36545844</identifier><language>eng</language><publisher>England: Taylor & Francis</publisher><subject>biologics ; Cohort Studies ; covid-19 ; COVID-19 - epidemiology ; Cross-Sectional Studies ; Humans ; immunosuppression ; Pandemics ; Prevalence ; psoriasis ; Psoriasis - drug therapy ; Psoriasis - epidemiology ; SARS-CoV-2 ; vaccines</subject><ispartof>The Journal of dermatological treatment, 2023-12, Vol.34 (1), p.2161297-2161297</ispartof><rights>2023 The Author(s). Published with license by Taylor & Francis Group, LLC. 2023</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c479t-c55db7856379bb8a329a0b95c602fb9f52d4b098b2bb9cc8b41b8ef3950f17143</citedby><cites>FETCH-LOGICAL-c479t-c55db7856379bb8a329a0b95c602fb9f52d4b098b2bb9cc8b41b8ef3950f17143</cites><orcidid>0000-0003-3661-9035 ; 0000-0003-3872-5704</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.tandfonline.com/doi/pdf/10.1080/09546634.2022.2161297$$EPDF$$P50$$Ginformaworld$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.tandfonline.com/doi/full/10.1080/09546634.2022.2161297$$EHTML$$P50$$Ginformaworld$$Hfree_for_read</linktohtml><link.rule.ids>314,776,780,860,2096,27479,27901,27902,59116,59117</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36545844$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kwee, Kevin V.</creatorcontrib><creatorcontrib>Murk, Jean-Luc</creatorcontrib><creatorcontrib>Yin, Qiqi</creatorcontrib><creatorcontrib>Visch, M. Birgitte</creatorcontrib><creatorcontrib>Davidson, Linda</creatorcontrib><creatorcontrib>de Jong, Elke M. G. J.</creatorcontrib><creatorcontrib>van den Reek, Juul M. P. A.</creatorcontrib><creatorcontrib>Tjioe, Milan</creatorcontrib><title>Prevalence, risk and severity of SARS-CoV-2 infections in psoriasis patients receiving conventional systemic, biologic or topical treatment during the COVID-19 pandemic: a cross-sectional cohort study (PsoCOVID)</title><title>The Journal of dermatological treatment</title><addtitle>J Dermatolog Treat</addtitle><description>The risk of SARS-CoV-2 infection does not appear to be increased for psoriasis patients using biologics compared to those on other treatments, but evidence is still limited.
(1) to estimate the prevalence of SARS-CoV-2 infection in patients with psoriasis, (2) to compare SARS-CoV-2 infection rates for different psoriasis treatments groups (biologic vs. systemic conventional vs. topical therapy) corrected for confounders and (3) to describe patients with severe COVID-19 for all treatment groups.
In this cross-sectional cohort study all patients received a questionnaire to gather data on psoriasis treatment, SARS-CoV-2 infections and related risk factors. Simultaneously, they underwent a blood test to screen for antibodies to SARS-CoV-2 N-antigen. Prevalence of SARS-CoV-2 infections was calculated and logistic regression and Cox proportional-hazards models were performed to determine the association between treatment group and SARS-CoV-2 infection risk, corrected for confounders. Patients with severe COVID-19 disease were described and the mortality rate per treatment group was calculated for the target population.
Patients were included between April 12 2021 and October 31 2021. Of 551 patients, 59 (10.7% (CI95% 8.3-13.6)) had experienced a SARS-CoV-2 infection, based on questionnaire data combined with serological data. In our study cohort, corrected for confounders, biologic or non-biologic systemic therapy users did not appear to have increased SARS-CoV-2 infection risk compared to patients using other treatment. Only 4 hospitalizations (0.7% (CI95% 0.2-1.0) were reported in our study population and no ICU admissions were reported. The rough mortality rate in the target cohort was 0.32% (CI95% 0.13-0.66) in all treatment groups.
Corrected for risk-mitigating behavior and vaccination status, a higher SARS-CoV-2 incidence for biologics or non-biologics systemics compared to other treatments could not be proven. Severe cases were infrequent in all treatment groups. This finding further strengthens treatment recommendations that systemic therapies for patients with psoriasis do not require preventive cessation for reduction of SARS-CoV-2 infection risk.</description><subject>biologics</subject><subject>Cohort Studies</subject><subject>covid-19</subject><subject>COVID-19 - epidemiology</subject><subject>Cross-Sectional Studies</subject><subject>Humans</subject><subject>immunosuppression</subject><subject>Pandemics</subject><subject>Prevalence</subject><subject>psoriasis</subject><subject>Psoriasis - drug therapy</subject><subject>Psoriasis - epidemiology</subject><subject>SARS-CoV-2</subject><subject>vaccines</subject><issn>0954-6634</issn><issn>1471-1753</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>0YH</sourceid><sourceid>EIF</sourceid><sourceid>DOA</sourceid><recordid>eNp9kt9u2yAYxa1p05p1e4RNXHZSnQEGY3bVKvsXqVKrdestAvw5pbNNBiRTnnMvNJykvdwV6ON3zkFwiuItwXOCG_wBS87qumJziimdU1ITKsWzYkaYICURvHpezCamnKCT4lWMDxiTqsbNy-KkqjnjDWOz4u9NgK3uYbRwjoKLv5AeWxRhC8GlHfIdur38flsu_F1JkRs7sMn5MeYtWkcfnI4uorVODsYUUQALbuvGFbJ-3OZRZnWP4i4mGJw9R8b53q-cRT6g5NfO5tMUQKchw6jdhEmb7gEtru-Wn0ois_fYTtqPSCMbfIxlPNwhK62_9yGhmDbtDp3dRL9XvX9dvOh0H-HNcT0tfn75_GPxrby6_rpcXF6VlgmZSst5a0TD60pIYxpdUamxkdzWmHZGdpy2zGDZGGqMtLYxjJgGukpy3BFBWHVaLA--rdcPah3coMNOee3UfuDDSumQnO1BcWMMq6qOkI4yw8AANA2hWtS1aFuQ2evs4LUO_vcGYlKDixb6Xo_gN1FRwQXmdUNxRvkB3T9HgO4pmmA1dUM9dkNN3VDHbmTdu2PExgzQPqkey5CBiwOQ_9mHQf_xoW9V0rvehy7o0bqoqv9n_AN5uMun</recordid><startdate>20231231</startdate><enddate>20231231</enddate><creator>Kwee, Kevin V.</creator><creator>Murk, Jean-Luc</creator><creator>Yin, Qiqi</creator><creator>Visch, M. Birgitte</creator><creator>Davidson, Linda</creator><creator>de Jong, Elke M. G. J.</creator><creator>van den Reek, Juul M. P. A.</creator><creator>Tjioe, Milan</creator><general>Taylor & Francis</general><general>Taylor & Francis Group</general><scope>0YH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0003-3661-9035</orcidid><orcidid>https://orcid.org/0000-0003-3872-5704</orcidid></search><sort><creationdate>20231231</creationdate><title>Prevalence, risk and severity of SARS-CoV-2 infections in psoriasis patients receiving conventional systemic, biologic or topical treatment during the COVID-19 pandemic: a cross-sectional cohort study (PsoCOVID)</title><author>Kwee, Kevin V. ; Murk, Jean-Luc ; Yin, Qiqi ; Visch, M. Birgitte ; Davidson, Linda ; de Jong, Elke M. G. J. ; van den Reek, Juul M. P. A. ; Tjioe, Milan</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c479t-c55db7856379bb8a329a0b95c602fb9f52d4b098b2bb9cc8b41b8ef3950f17143</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>biologics</topic><topic>Cohort Studies</topic><topic>covid-19</topic><topic>COVID-19 - epidemiology</topic><topic>Cross-Sectional Studies</topic><topic>Humans</topic><topic>immunosuppression</topic><topic>Pandemics</topic><topic>Prevalence</topic><topic>psoriasis</topic><topic>Psoriasis - drug therapy</topic><topic>Psoriasis - epidemiology</topic><topic>SARS-CoV-2</topic><topic>vaccines</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kwee, Kevin V.</creatorcontrib><creatorcontrib>Murk, Jean-Luc</creatorcontrib><creatorcontrib>Yin, Qiqi</creatorcontrib><creatorcontrib>Visch, M. Birgitte</creatorcontrib><creatorcontrib>Davidson, Linda</creatorcontrib><creatorcontrib>de Jong, Elke M. G. J.</creatorcontrib><creatorcontrib>van den Reek, Juul M. P. A.</creatorcontrib><creatorcontrib>Tjioe, Milan</creatorcontrib><collection>Taylor & Francis Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>The Journal of dermatological treatment</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kwee, Kevin V.</au><au>Murk, Jean-Luc</au><au>Yin, Qiqi</au><au>Visch, M. Birgitte</au><au>Davidson, Linda</au><au>de Jong, Elke M. G. J.</au><au>van den Reek, Juul M. P. A.</au><au>Tjioe, Milan</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Prevalence, risk and severity of SARS-CoV-2 infections in psoriasis patients receiving conventional systemic, biologic or topical treatment during the COVID-19 pandemic: a cross-sectional cohort study (PsoCOVID)</atitle><jtitle>The Journal of dermatological treatment</jtitle><addtitle>J Dermatolog Treat</addtitle><date>2023-12-31</date><risdate>2023</risdate><volume>34</volume><issue>1</issue><spage>2161297</spage><epage>2161297</epage><pages>2161297-2161297</pages><issn>0954-6634</issn><eissn>1471-1753</eissn><abstract>The risk of SARS-CoV-2 infection does not appear to be increased for psoriasis patients using biologics compared to those on other treatments, but evidence is still limited.
(1) to estimate the prevalence of SARS-CoV-2 infection in patients with psoriasis, (2) to compare SARS-CoV-2 infection rates for different psoriasis treatments groups (biologic vs. systemic conventional vs. topical therapy) corrected for confounders and (3) to describe patients with severe COVID-19 for all treatment groups.
In this cross-sectional cohort study all patients received a questionnaire to gather data on psoriasis treatment, SARS-CoV-2 infections and related risk factors. Simultaneously, they underwent a blood test to screen for antibodies to SARS-CoV-2 N-antigen. Prevalence of SARS-CoV-2 infections was calculated and logistic regression and Cox proportional-hazards models were performed to determine the association between treatment group and SARS-CoV-2 infection risk, corrected for confounders. Patients with severe COVID-19 disease were described and the mortality rate per treatment group was calculated for the target population.
Patients were included between April 12 2021 and October 31 2021. Of 551 patients, 59 (10.7% (CI95% 8.3-13.6)) had experienced a SARS-CoV-2 infection, based on questionnaire data combined with serological data. In our study cohort, corrected for confounders, biologic or non-biologic systemic therapy users did not appear to have increased SARS-CoV-2 infection risk compared to patients using other treatment. Only 4 hospitalizations (0.7% (CI95% 0.2-1.0) were reported in our study population and no ICU admissions were reported. The rough mortality rate in the target cohort was 0.32% (CI95% 0.13-0.66) in all treatment groups.
Corrected for risk-mitigating behavior and vaccination status, a higher SARS-CoV-2 incidence for biologics or non-biologics systemics compared to other treatments could not be proven. Severe cases were infrequent in all treatment groups. This finding further strengthens treatment recommendations that systemic therapies for patients with psoriasis do not require preventive cessation for reduction of SARS-CoV-2 infection risk.</abstract><cop>England</cop><pub>Taylor & Francis</pub><pmid>36545844</pmid><doi>10.1080/09546634.2022.2161297</doi><tpages>1</tpages><orcidid>https://orcid.org/0000-0003-3661-9035</orcidid><orcidid>https://orcid.org/0000-0003-3872-5704</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0954-6634 |
| ispartof | The Journal of dermatological treatment, 2023-12, Vol.34 (1), p.2161297-2161297 |
| issn | 0954-6634 1471-1753 |
| language | eng |
| recordid | cdi_pubmed_primary_36545844 |
| source | Taylor & Francis Open Access; MEDLINE; DOAJ Directory of Open Access Journals |
| subjects | biologics Cohort Studies covid-19 COVID-19 - epidemiology Cross-Sectional Studies Humans immunosuppression Pandemics Prevalence psoriasis Psoriasis - drug therapy Psoriasis - epidemiology SARS-CoV-2 vaccines |
| title | Prevalence, risk and severity of SARS-CoV-2 infections in psoriasis patients receiving conventional systemic, biologic or topical treatment during the COVID-19 pandemic: a cross-sectional cohort study (PsoCOVID) |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-05T05%3A12%3A54IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Prevalence,%20risk%20and%20severity%20of%20SARS-CoV-2%20infections%20in%20psoriasis%20patients%20receiving%20conventional%20systemic,%20biologic%20or%20topical%20treatment%20during%20the%20COVID-19%20pandemic:%20a%20cross-sectional%20cohort%20study%20(PsoCOVID)&rft.jtitle=The%20Journal%20of%20dermatological%20treatment&rft.au=Kwee,%20Kevin%20V.&rft.date=2023-12-31&rft.volume=34&rft.issue=1&rft.spage=2161297&rft.epage=2161297&rft.pages=2161297-2161297&rft.issn=0954-6634&rft.eissn=1471-1753&rft_id=info:doi/10.1080/09546634.2022.2161297&rft_dat=%3Cproquest_pubme%3E2757056820%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2757056820&rft_id=info:pmid/36545844&rft_doaj_id=oai_doaj_org_article_5bbb433f11f24b4ebee8812a7667dde9&rfr_iscdi=true |